Journal Article

Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease

Lorin, Jeffrey D, Weintraub, William S, Kostuk, William, Sedlis, Steven P, Hartigan, Pamela M, Teo, Koon K, Boden, William E, Maron, David J, Berman, Daniel, Dada, Marcin, Mancini, G.B. John, Chaitman, Bernard R, Spertus, John A

2015

Overview

Patients in the COURAGE trial who gave permission for long-term survival tracking were followed for up to 15 years. There was no difference between the PCI and medical-therapy groups in all-cause mortality. Percutaneous coronary intervention (PCI) relieves angina and reduces the extent of myocardial ischemia in patients with stable ischemic heart disease, but trials have not shown a survival benefit. By contrast, among patients with acute ST-segment elevation myocardial infarction, PCI has been shown to increase survival rates, 1 , 2 and among patients with non–ST-segment elevation myocardial infarction, PCI has been shown to improve long-term survival, with a reduction in both early and late cardiac events. 3 , 4 Nevertheless, uncertainty persists about the effect of PCI on long-term survival among patients with stable ischemic heart disease. In the Clinical Outcomes Utilizing Revascularization and Aggressive . . .

• Publisher: Massachusetts Medical Society
• Subject: Aged / Angina / Angina pectoris / Angioplasty / Cardiovascular disease / Clinical trials / Combined Modality Therapy / Coronary artery disease / Female / Follow-Up Studies / Heart diseases / Humans / Ischemia / Kaplan-Meier Estimate / Male / Middle Aged / Mortality / Myocardial Ischemia - drug therapy / Myocardial Ischemia - mortality / Myocardial Ischemia - therapy / Patients / Percutaneous Coronary Intervention / Proportional Hazards Models / Survival / United States - epidemiology / United States Department of Veterans Affairs